Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 17/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289078 | 1.00 | GCK (0.36) | GCKKCNH2NPC1ALDH1A1RAB9A | |
| SCHEMBL2199548 | 0.80 | GCK (0.63) | GCK | |
| SCHEMBL2199553 | 0.80 | GCK (0.63) | GCK | |
| SCHEMBL1445554 | 0.77 | KCNH2 (0.66) | GCKKCNH2 | |
| SCHEMBL2646066 | 0.77 | KCNH2 (0.66) | GCKKCNH2 | |
| SCHEMBL1445670 | 0.76 | CNR2 (0.36) | NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1445671 | 0.76 | CNR2 (0.36) | NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL13585122 | 0.73 | GCK (0.39) | GCK | |
| SCHEMBL13585126 | 0.73 | GCK (0.39) | GCK | |
| SCHEMBL27948150 | 0.73 | GCK (0.39) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | GCK 1/4885KCNH2 1074/4885NPC1 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.